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Abstract: Critically ill patients are predisposed to stress-induced hyperglycemia. Recent 
  evidence suggests that uncontrolled hyperglycemia is associated with poor outcomes within the 
population of surgical and medical intensive care units. We retrospectively audited our practice 
in the management of hyperglycemia in the critically ill, in order to identify reasons and periods 
of time that deviations in blood glucose control are most likely, and to make recommendations 
on how to improve this. Our study showed poor compliance with the current recommenda-
tions for glycemic control in the critically ill and highlighted the need for a successful protocol 
for glycemic control in our institution. That should be carefully coordinated with the level of 
nutritional support and metabolic status of the acutely ill patient.
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Introduction
Hyperglycemia and insulin resistance are common in critically ill patients and more 
pronounced among patients having sepsis, burns, trauma, and cardiothoracic surgery.1 
Hyperglycemia was previously considered an adaptive response essential for survival 
and was not routinely controlled in intensive care units (ICUs).2,3 However, more 
recent evidence suggests that hyperglycemia in critically ill patients is associated 
with worse outcomes. Multiple randomized control trials have evaluated the role of 
intensive insulin therapy in intensive care patients.4–17 From these studies controversy 
exists with regards to the target blood glucose level during insulin therapy. Several 
studies have evaluated glycemic control in surgical, medical and mixed ICU patient 
populations.
The largest surgical trial was performed by Van den Berghe and colleagues and was 
a randomized study of 1548 adult surgical patients receiving mechanical   ventilation 
on ICU (62% had undergone cardiothoracic surgery) who were   randomized to 
  conventional blood glucose management or intensive insulin therapy.9 Insulin therapy 
was initiated when the blood glucose concentration reached 12 mmol/L in the con-
ventional group versus 6.1 mmol/L in the intensive treatment group and the target 
range was 10–11.1 mmol/L (180 to 200 mg/dL) in the conventional group compared 
to 4.4–6.1 mmol/L (80 to 110 mg/dL) in the intensive insulin therapy group. All 
patients were given 200 to 300 g of intravenous glucose during the first 24 hours of ICU 
admission, with aggressive nutritional support to reach the caloric goal by ICU day 2 
(the majority with mixed enteral and parenteral nutrition). A 12 month risk reduction 
in mortality of 43% (P , 0.036) was demonstrated in the intensive therapy cohort. 
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Risk reductions in this group were also seen for other 
outcomes including a 46% risk reduction in bloodstream 
infections. This study, however, had several limitations and 
differences from daily practice. First, the overall ICU hospital 
mortality rate was large in the control group, which may 
have confounded the benefit of intensive insulin therapy. 
In   addition, the large infusion of glucose during the first 
24 hours of ICU admission followed by aggressive nutrition 
may have additionally benefited the intensive insulin group 
as they were rescued by early aggressive therapy.
The Leuven Medical was the only large randomized 
trial that evaluated the effect of glycemic control in medical 
ICU patients and assigned 2000 patients to intensive insulin 
therapy or conventional glucose management.10 As in the 
surgical trial, intensive therapy targeted a blood glucose level 
of 80 to 110 mg/dL, whereas conventional therapy targeted a 
blood glucose level of 180 to 200 mg/dL. The glucose infu-
sion in the first 24 hours was followed by intensive nutritional 
management. The insulin protocols were identical to the 
surgical trial. Intensive insulin therapy did not significantly 
change overall mortality when compared with conventional 
management. However, the intensive insulin therapy arm had 
a higher mortality when ICU stay was shorter than 3 days but 
was associated with reduced mortality if longer than 3 days. 
Intensive therapy was also associated with reduced acute 
kidney injury rate, duration of mechanical ventilation, ICU 
length of stay, and total hospital length of stay. Hypoglycemia 
was much more common in the intensive therapy group.
The most robust trial to date is the multicenter 
  Normoglycemia in Intensive Care Evaluation Survival Using 
Glucose Algorithm Regulation (NICE-SUGAR) trial which 
raised the question of potential treatment-related harm and also 
documented significant hypoglycemia. The NICE-SUGAR 
trial randomly assigned 6022 medical and surgical ICU patients 
to either intensive insulin therapy (target blood glucose level 
of 81 to 108 mg/dL [4.5–6 mmol/L]) or conventional glucose 
control (target blood glucose of ,180 mg/dL [,10 mmol/L]).9 
Although the conventional glucose group was defined only by a 
maximal blood glucose target, the insulin infusion was reduced 
and then discontinued if the blood glucose level dropped below 
144 mg/dL (8.0 mmol/L). The intensive insulin therapy group 
had a significantly higher 90 day mortality and significantly 
higher incidence of severe hypoglycemia, defined as blood 
glucose ,40 mg/dL (2.2 mmol/L). Therefore, a blood glucose 
target of 8.0–10 mmol/L (144–180 mg/dL) rather than a more 
stringent target (eg, 81–108 mg/dL [4.5–6.0 mmol/L]) or a 
more liberal target (eg, 180–200 mg/dL [10–11.1 mmol/L]), 
avoids marked hyperglycemia, while minimizing the risk of 
both iatrogenic hypoglycemia and other harms associated with 
a lower blood glucose target.
Materials and methods
The purpose of the study was to record blood glucose con-
centrations, in patients admitted to a general ICU, for the 
first 48 hours after ICU admission and compare the results to 
an audit standard of 8.0–10.0 mmol/L, based on the NICE-
SUGAR study and international recommendations for gly-
cemic control in critically ill patients.10 We aimed to identify 
reasons and periods of time where deviations in blood glucose 
control are most likely and to make recommendations on how 
to improve this. We decided to undertake this clinical audit 
because the findings of the Van den Berghe studies were not 
replicated by other investigators and we were concerned that 
the widely accepted Van den Berghe approach for intensive 
blood glucose control increases mortality, as reported by the 
NICE-SUGAR trial and recent meta-analyses.11,18 Our aim: to 
change current practice and patient care in accordance with 
the latest recommendations and evidence based medicine.
A retrospective review of 20 patients receiving mechani-
cal ventilation in an eight-bedded general (medical-surgical) 
ICU of a district general hospital was conducted. An audit 
tool was developed to evaluate the pattern of glycemic control 
over time and data was collected from the ICU observation 
charts for the first 48 hours after ICU admission. Blood 
samples for glucose measurement were obtained by means 
of arterial catheters, and intravenous infusion of insulin 
in saline was used for control of blood glucose. All these 
patients received intravenous fluids in a traditional manner 
and after vital signs became stabilized, enteral nutritional 
support was provided as soon as possible.
Results
Data was collected from a total of 20 patients. Sixty-five 
percent (13) of these were male and the majority of the 
patients (55%) were aged between 70 and 80 years old. 
Fifteen percent (3) of these patients were diabetics and 45% 
(9) were surgical patients. All 20 patients were mechanically 
ventilated for a minimum period of 48 hours. The average fre-
quency of blood glucose monitoring was 2.6 hours. The mean 
number of blood glucose samples per patient in 48 hours was 
18.45. Twenty percent of the patients received intravenous 
infusion of insulin in order to achieve glycemic control. 
Only 22.2% of the patients with blood glucose level greater 
than 10 mmol/L, received insulin. Only 15% of the patients 
with blood sugar level less than 8 mmol/L received enteral 
nutrition. One case of hypoglycemia was seen (blood glucose 
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level, #40 mg/dL [2.2 mmol/L]) in a non-diabetic patient 
being treated with an insulin infusion. None of the patients 
met the standard of 8.0–10.0 mmol/L for the audit period of 
48 hours. Figure 1 shows the pattern of glycemic control in 
our ICU for the first 48 hours after ICU admission.
Discussion
Hyperglycemia is associated with poor clinical outcomes in 
critically ill patients. Too tight a target blood sugar range 
is difficult to meet and may be leading to more morbidity 
due to hypoglycemic episodes. For hyperglycemic criti-
cally ill patients we recommend a blood glucose target of 
8.0–10 mmol/L (144–180 mg/dL). To achieve this target we 
suggest that use of intravenous fluids that contain glucose 
should be minimized and administration of insulin be com-
menced if blood glucose exceeds 10.0 mmol/L (180 mg/dL), 
and adjusted when needed to maintain blood glucose of 
8.0–10.0 mmol/L (144–180 mg/dL). Our purpose is to design 
a successful protocol for glycemic control in our institution. 
The majority of suggested protocols demand a minimum of 
hourly glucose monitoring for successful glycemic target 
achievement while reducing the risk of hypoglycemia.19 For 
the implementation of insulin protocols for strict glycemic 
control in our ICU, there is a need for an automated continu-
ous vascular blood glucose monitor which is still undergoing 
evaluation in the United Kingdom.20 The strategy of glyce-
mic control should be carefully coordinated with the level 
of nutritional support and metabolic status of the critically 
ill patient. We suggest an uninterrupted feeding regime in 
order to avoid hypoglycemia, which is an independent risk 
factor for death after adjustment for age, severity of illness, 
diabetes, renal failure, and mechanical ventilation.21 Thus, 
glucose control protocols should include specific algorithms 
for managing hypoglycemic events in critically ill patients. 
Early glucose control has the potential to reduce ICU or 
hospital length of stay for all patients admitted to the ICU. 
By ensuring compliance, developing protocols and incorpo-
rating a multidisciplinary approach, clinicians will achieve 
blood glucose control in the critically ill population and 
improve outcomes. A re-audit will be performed 6 months 
after implementation of changes.
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Figure 1 Pattern of glycemic control in our ICU for the first 48 hours after ICU admission.
Abbreviation: ICU, intensive care unit.
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